Second line drug for concomitant use with other appropriate anti-tubercular drugs when the first line drugs are ineffective.
1 gm daily intramuscularly, followed by 1g i.m. 2-3 times weekly.
Audiometric, renal function tests and liver function tests must be performed at regular intervals. Paediatrics: Not recommended. Pregnanacy: Safety not established. Lactation: Use with caution.
Tinnitus, vertigo, leucopenia, hypokalemia, urticaria, skin rash, fever, pain and induration at injection site, abnormalities in liver functions.
Co-administration of aminoglycoside and other polypeptide antibiotics may increase risk of respiratory paralysis and renal dysfunction. Non depolarising neuromuscular blocking agent enhances neuromuscular blockade due to synergistic effect on myoneural function